INMB_OUT_1 [2025-03-19 15:55:40 -0400] 2028 Bytes | 613 tokens | Cum: 613 tkns (7.66% of 8k)
==========================================================================

Alright, let’s light it up, because it's 03:55:38 PM on Wednesday March 19, 2025 ET (UTC-0400), and I'm charging into INmune Bio (INMB), popping from 7.19 to 8.3464. Is this our star stock of the day, or just a quick blip on the radar? I've got the scoop—time to analyze!

Here's the first list of news for INmune Bio:

C1 - Mar-02-25 09:28AM - Why INmune Bio, Inc. (INMB) is Skyrocketing So Far in 2025
C2 - Feb-12-25 09:51AM - INmune Bio price target raised to $23 from $22 at Scotiabank
C3 - Feb-12-25 09:51AM 07:00AM - INmune Bio Opens Phase II in High Dose Cohort of INKmune Trial in Prostate Cancer
C4 - Feb-10-25 07:00AM - INmune Bio Announces Plan to Submit FDA Biologics License Application (BLA) Seeking Approval of CORDStrom for Treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB)
C5 - Feb-03-25 08:11PM - Why INmune Bio Inc (INMB) Is Skyrocketing So Far In 2025
C6 - Jan-28-25 08:00AM - INmune Bio Inc. Expands INKmune Trial in Prostate Cancer to Veterans
C7 - Jan-12-25 06:05AM - Raymond James Predicts Up to ~930% Rally for These 2 Strong Buy Stocks
C8 - Dec-10-24 08:00AM - INmune Bio Inc. Completes Repayment of Silicon Valley Bank Debt

ONLY 3 RULES for AI:
==============
1) This is a document retrieval system. You are the analyst-investigator.
2) You can request items from any list to get more details about INmune Bio (INMB)
3) AFTER requesting and reading News and SEC filings you'll get tokens to write a summary, set a score and high price target, and finally take an exit quiz.
Now, your response should be only 2 or 3 chars. You can say ex., C1, C2, etc., or NEX
The NEX command delivers the NEXt list of News/SEC/Metrics
There are several more lists that use our unified document retrieval system in subsequent prompts.

Thank you for your analysis of INmune Bio.
Your predictons will be compared to reality to rate your accuracy. Try to predict accurately. GOOD LUCK!

Please request a document, read, summarize and score. Say something like "C1".

INMB_OUT_3 [2025-03-19 15:55:42 -0400] 969 Bytes | 260 tokens | Cum: 875 tkns (10.94% of 8k)
==========================================================================

Showing C1 (chunk 1 of 4): C1:
**Why INmune Bio, Inc. (INMB) is Skyrocketing So Far in 2025**
Date: Mar-02-25 09:28AM
Source: (Insider Monkey)
URL: https://finance.yahoo.com/news/why-inmune-bio-inc-inmb-142833790.html

We recently published an article titledWhy These 15 Biotech Stocks Are Skyrocketing So Far In 2025.In this article, we are going to take a look at where INmune Bio, Inc. (NASDAQ:INMB) stands against the other biotech stocks.

No matter the market environment, you’ll always find entertainment in the biotech space. There will always be biotech stocks making huge swings in both directions and these stocks can make or break your portfolio in a very small amount of time due to the nature of how important clinical trial results are for these companies.

The United Nations forecasts that the over-65 age group will grow by 150% from 800 million in 2024 to 2 billion by 2067. This "older, richer & sicker" pop

-- More? (MOR) or Next section? (NEX)

INMB_OUT_5 [2025-03-19 15:55:44 -0400] 872 Bytes | 292 tokens | Cum: 1169 tkns (14.61% of 8k)
==========================================================================

We present this news so you can catch the big movers from recently breaking news.
Here's a list of news articles you can literally read just by asking.
Usually the first item is the most important.

A1 - 2025-03-18T20:36:00Z - INmune Bio: CORDStrom Is A Game-Changer, As Investors Await Alzheimer's Results (INMB)...
A2 - 2025-03-10T10:19:29Z - INmune Bio, Inc. (NASDAQ:INMB) Given Consensus Rating of "Buy" by Analysts...
A3 - 2025-03-02T14:33:58Z - Why INmune Bio, Inc. (INMB) is Skyrocketing So Far in 2025...
A4 - 2025-03-02T14:28:33Z - Why INmune Bio, Inc. (INMB) is Skyrocketing So Far in 2025...
A5 - 2025-02-24T04:13:28Z - $INMB | Learn to Evaluate ($INMB) using the Charts (INMB)...

Request an article by its reference number. (Ex., "A1" gets the first item)
You may also say NEX to go to the next listing.
Response to this prompt limited to 3 chars.

INMB_OUT_7 [2025-03-19 15:55:45 -0400] 967 Bytes | 265 tokens | Cum: 1436 tkns (17.95% of 8k)
==========================================================================

Showing A1 (chunk 1 of 4): A1:
**INmune Bio: CORDStrom Is A Game-Changer, As Investors Await Alzheimer's Results (INMB)**Date: 2025-03-18Source: {'uri': 'seekingalpha.com', 'dataType': 'news', 'title': 'Seeking Alpha'}URL: https://seekingalpha.com/article/4768547-inmune-bio-cordstrom-is-a-game-changer-as-investors-await-alzheimers-resultsDespite high risks, the combined upside potential of 9.8x-144.8x for both programs warrants a very bullish rating for INmune Bio.

Thesis

INmune Bio (NASDAQ:INMB) has recently announced that it will be seeking approval of CORDStrom for the treatment of recessive dystrophic epidermolysis bullosa [RDEB] after favorable investigator-initiated trial results. CORDStrom was out of focus of investors. The FDA recently

I am a long-term investor focused on growth markets, AI and biotech opportunities in my more volatile portfolio. I try to look for undervalued and under-the-radar stocks

-- More? (MOR) or Next section? (NEX)

INMB_OUT_9 [2025-03-19 15:55:47 -0400] 905 Bytes | 289 tokens | Cum: 1727 tkns (21.59% of 8k)
==========================================================================

This is our final list of news.
News AI can literally read just by asking.
Don't miss the breaking news!

B1 - 2024-07-19T21:53:47Z - Inmune Bio re-elects directors, ratifies auditor - Investing.com
B2 - 2024-07-12T11:37:58Z - Zura Bio initiates exchange offer for warrants By Investing.com - Investing.com
B3 - 2024-05-30T12:00:00Z - INmune Bio Inc. to Join Russell 3000® Index
B4 - 2024-05-09T20:05:00Z - INmune Bio Inc. Announces First Quarter 2024 Results and Provides Business Update
B5 - 2024-03-28T20:01:00Z - INmune Bio Inc. Announces Year End 2023 Results and Provides a Q4 Business Update
B6 - 2024-03-26T20:01:00Z - INmune Bio Inc. to Report Fourth Quarter 2023 Financial Results and Provide a Corporate Update on Thursday, March 28

Request an article by its reference number. (Ex., "B1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

INMB_OUT_11 [2025-03-19 15:55:50 -0400] 472 Bytes | 148 tokens | Cum: 1877 tkns (23.46% of 8k)
==========================================================================

Showing B4 (chunk 1 of 1): B4:
**INmune Bio Inc. Announces First Quarter 2024 Results and Provides Business Update**Date: Unknown DateSource: Unknown SourceURL: https://www.globenewswire.com/news-release/2024/05/09/2879206/0/en/INmune-Bio-Inc-Announces-First-Quarter-2024-Results-and-Provides-Business-Update.htmlCompany to Host Conference Call Today, May 9, at 4:30pm ET Company to Host Conference Call Today, May 9, at 4:30pm ET

-- More? (MOR) or Next section? (NEX)

INMB_OUT_13 [2025-03-19 15:55:51 -0400] 1169 Bytes | 302 tokens | Cum: 2226 tkns (27.82% of 8k)
==========================================================================

This is our list of SEC filings.
Read it just by asking.
Don't miss breaking filings!

S1 - 2025-03-04 8-K Item 7.01. Regulation FD Disclosure.

INmune Bio Inc. (the Company) has prepared a slide deck that the Company intends to use in presentations from time to time (the Presentation). The Presentation is furnished as Exhibit 99.1 to this Curr Report on Form 8-K.

The information...

S2 - 2025-02-10 8-K Item 1.01 Entry into a Material Definitive Agrmt.

On February 6, 2025, INmune Bio Inc. (the Company) and Great Ormond Street Hospital NHS Foundation Trust (GOSH) entered into a license agreement (the License Agrmt) for the exclusive commercial use to clinical trial data...

S3 - 2025-02-10 8-K Item 7.01. Regulation FD Disclosure.

INmune Bio Inc. (the Company) has prepared a slide deck that the Company intends to use in presentations from time to time (the Investor Presentation) and a slide deck that the Company intends to use in webinar presentations from time to tim...

Request filing by its reference number. (Ex., "S1" gets the first item)
You can say NEX to go to the next listing - but what fun is that?
Response limited to 3 chars.

INMB_OUT_15 [2025-03-19 15:55:53 -0400] 967 Bytes | 218 tokens | Cum: 2446 tkns (30.58% of 8k)
==========================================================================

Showing S2 (chunk 1 of 4): S2:
Item 1.01 Entry into a Material Definitive Agreement.

On February 6, 2025, INmune Bio Inc. (the Company) and Great Ormond Street Hospital NHS Foundation Trust (GOSH) entered into a license agreement (the License Agreement) for the exclusive commercial use to clinical trial data associated with the Mission EB study (the Mission EB study) investigating the potential of CORDStrom to treat recessive dystrophic epidermolysis bullosa (RDEB) in pediatric patients. The Company owns the intellectual property covering CORDStrom, the investigational medicinal product used in the Mission EB study. In addition, the Company owns intellectual property and maintains trade secret protections covering the manufacturing of CORDStrom.

The Company intends to use the license to prepare applications seeking marketing authorization of CORDStrom for treatment of pediatric RDEB in each of the U.S. Food and

-- More? (MOR) or Next section? (NEX)

INMB_OUT_17 [2025-03-19 15:55:54 -0400] 967 Bytes | 220 tokens | Cum: 2668 tkns (33.35% of 8k)
==========================================================================

Showing S2 (chunk 2 of 4): Drug Administration (FDA), European Medicines Agency (EMA) and Medicines and Healthcare Products Regulatory Agency (MHRA).

Under the terms of the License Agreement, the Company has agreed to an upfront payment of 250,000 (approximately $0.3 million) within thirty (30) days of the effective date of the License Agreement and a single milestone payment up to 6,000,000 (approximately $7.5 million) due on the first marketing authorization to be granted by the FDA, EMA or MHRA. The Company has also agreed to certain patient access obligations, including sponsoring the supply of CORDStrom to United Kingdom patients enrolled in an open label continuation of the Mission EB study.

The term of the License Agreement shall continue in effect ten (10) years. The Company may terminate the License Agreement by delivering sixty (60) days written notice to GOSH upon (i) notice from the FDA, MHRA, or EM

-- More? (MOR) or Next section? (NEX)

INMB_OUT_19 [2025-03-19 15:56:11 -0400] 3254 Bytes | 777 tokens | Cum: 3452 tkns (43.15% of 8k)
==========================================================================

This is our set of metrics.
Please analyze the numbers.

+---------------------+--------------------+----------------------+-------------------------+---------------------------+--------------------------+
| Prev Close: 7.19 | RSI (14): 52.49 | Perf Quarter: 75.63% | Insider Trans: 0.13% | Sales Q/Q: -100.00% | ROE: -98.97% |
+---------------------+--------------------+----------------------+-------------------------+---------------------------+--------------------------+
| Target Price: 23.33 | ATR (14): 0.70 | Index: RUT | Option/Short: Yes / Yes | Sales past 5Y: 401.55% | ROI: -105.94% |
+---------------------+--------------------+----------------------+-------------------------+---------------------------+--------------------------+
| Price: 8.34 | SMA20: 3.53% | Market Cap: 221.83M | Short Float: 28.65% | Income: -41.27M | Sales Surprise: -100.00% |
+---------------------+--------------------+----------------------+-------------------------+---------------------------+--------------------------+
| Change: 16.03% | SMA50: 3.66% | Shs Outstand: 22.17M | Short Ratio: 14.34 | Employees: 17 | EPS Surprise: -18.41% |
+---------------------+--------------------+----------------------+-------------------------+---------------------------+--------------------------+
| Volume: 297,317 | SMA200: 21.72% | Shs Float: 18.91M | Short Interest: 5.42M | Debt/Eq: 0.08 | P/E: - |
+---------------------+--------------------+----------------------+-------------------------+---------------------------+--------------------------+
| Avg Volume: 377.85K | Perf Week: -4.88% | Inst Own: 23.33% | Beta: 1.92 | Sales Y/Y TTM: -81.25% | Earnings: Oct 31 AMC |
+---------------------+--------------------+----------------------+-------------------------+---------------------------+--------------------------+
| Rel Volume: 0.83 | Perf Month: -9.13% | Insider Own: 28.90% | Sales: 0.04M | Profit Margin: -98266.67% | |
+---------------------+--------------------+----------------------+-------------------------+---------------------------+--------------------------+

The next section covers any insider trading.
If this section is blank, it's because there've been no recent filings.

Now we've reached the end of the analysis.
You are now allotted tokens to make a final analysis summary.
Please don't use tokens to explain why you didn't have enough information.
Save that for the survey that comes last.

Finish the summary with two scores: MARKET_SCORE[] and PRICE_TARGET[]

If you think there's a 90% likelihood of an upward moves, say: MARKET_SCORE[90]
If you think the high today will be 50% higher, add to the price. Eg., If the price is $5.00, add 50%: PRICE_TARGET[$7.50]
PRICE_TARGET is the highest it is expected to rise today, so it cannot be less than the current price.

After you have completed that, please provide a thought-provoking take, 6-10 words, to use for the headline of this news story.
Like this: AI_RPT_HEADLINE: [6-10 words headline for news story from first summary paragraph]

INMB_OUT_21 [2025-03-19 15:56:13 -0400] 561 Bytes | 131 tokens | Cum: 3995 tkns (49.94% of 8k)
==========================================================================

Finally, if more data could have improved your confidence which would you have chosen? **Choose one option:**
-> X0 <- Nothing more would have helped my analysis
-> X1 <- More stock-specific news
-> X2 <- More SEC filings & insider data
-> X3 <- Broader sector & market news
-> X4 <- General market sentiment & AI confidence levels
-> X5 <- AI's past analysis on similar companies
-> X6 <- More financial metrics
-> X7 <- AI's past analysis on this exact company
-> X8 <- Something altogether different (explain...)

INMB_IN_23 [2025-03-19 15:56:14 -0400] 126 Bytes | 29 tokens | Cum: 4034 tkns (50.42% of 8k)
==========================================================================

====================================
[2025-03-19 12:56:14] # Analysis Completed
Elapsed Time: 36.19 seconds